|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KANK2 |
Gene summary for KANK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KANK2 | Gene ID | 25959 |
| Gene name | KN motif and ankyrin repeat domains 2 | |
| Gene Alias | ANKRD25 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q63ZY3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25959 | KANK2 | male-WTA | Human | Thyroid | PTC | 2.47e-42 | 5.52e-01 | 0.1037 |
| 25959 | KANK2 | PTC01 | Human | Thyroid | PTC | 1.59e-08 | 2.42e-01 | 0.1899 |
| 25959 | KANK2 | PTC03 | Human | Thyroid | PTC | 9.21e-03 | 2.06e-01 | 0.1784 |
| 25959 | KANK2 | PTC04 | Human | Thyroid | PTC | 1.49e-15 | 4.44e-01 | 0.1927 |
| 25959 | KANK2 | PTC05 | Human | Thyroid | PTC | 2.27e-31 | 9.27e-01 | 0.2065 |
| 25959 | KANK2 | PTC06 | Human | Thyroid | PTC | 4.12e-45 | 9.55e-01 | 0.2057 |
| 25959 | KANK2 | PTC07 | Human | Thyroid | PTC | 1.43e-35 | 6.83e-01 | 0.2044 |
| 25959 | KANK2 | ATC09 | Human | Thyroid | ATC | 2.13e-20 | 7.44e-01 | 0.2871 |
| 25959 | KANK2 | ATC11 | Human | Thyroid | ATC | 4.95e-04 | 4.40e-01 | 0.3386 |
| 25959 | KANK2 | ATC12 | Human | Thyroid | ATC | 8.25e-20 | 5.70e-01 | 0.34 |
| 25959 | KANK2 | ATC13 | Human | Thyroid | ATC | 5.92e-53 | 1.22e+00 | 0.34 |
| 25959 | KANK2 | ATC1 | Human | Thyroid | ATC | 6.16e-19 | 8.21e-01 | 0.2878 |
| 25959 | KANK2 | ATC2 | Human | Thyroid | ATC | 4.62e-08 | 8.14e-01 | 0.34 |
| 25959 | KANK2 | ATC3 | Human | Thyroid | ATC | 1.45e-07 | 4.53e-01 | 0.338 |
| 25959 | KANK2 | ATC4 | Human | Thyroid | ATC | 2.34e-30 | 6.79e-01 | 0.34 |
| 25959 | KANK2 | ATC5 | Human | Thyroid | ATC | 2.58e-57 | 1.31e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
| GO:0071496113 | Thyroid | PTC | cellular response to external stimulus | 158/5968 | 320/18723 | 4.12e-11 | 1.47e-09 | 158 |
| GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
| GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
| GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
| GO:0031668113 | Thyroid | PTC | cellular response to extracellular stimulus | 120/5968 | 246/18723 | 2.13e-08 | 4.91e-07 | 120 |
| GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
| GO:0031669112 | Thyroid | PTC | cellular response to nutrient levels | 106/5968 | 215/18723 | 6.96e-08 | 1.44e-06 | 106 |
| GO:19019908 | Thyroid | PTC | regulation of mitotic cell cycle phase transition | 138/5968 | 299/18723 | 1.44e-07 | 2.78e-06 | 138 |
| GO:0030518111 | Thyroid | PTC | intracellular steroid hormone receptor signaling pathway | 63/5968 | 116/18723 | 4.53e-07 | 7.41e-06 | 63 |
| GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
| GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
| GO:00000829 | Thyroid | PTC | G1/S transition of mitotic cell cycle | 102/5968 | 214/18723 | 9.48e-07 | 1.43e-05 | 102 |
| GO:0071383112 | Thyroid | PTC | cellular response to steroid hormone stimulus | 98/5968 | 204/18723 | 9.83e-07 | 1.47e-05 | 98 |
| GO:00448439 | Thyroid | PTC | cell cycle G1/S phase transition | 112/5968 | 241/18723 | 1.37e-06 | 1.96e-05 | 112 |
| GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
| GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
| GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
| GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
| GO:0001667112 | Thyroid | PTC | ameboidal-type cell migration | 198/5968 | 475/18723 | 3.36e-06 | 4.34e-05 | 198 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KANK2 | SNV | Missense_Mutation | c.2525N>T | p.Ser842Leu | p.S842L | Q63ZY3 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KANK2 | SNV | Missense_Mutation | c.2231N>C | p.Ser744Thr | p.S744T | Q63ZY3 | protein_coding | deleterious(0.01) | possibly_damaging(0.465) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| KANK2 | SNV | Missense_Mutation | c.2542N>A | p.Asp848Asn | p.D848N | Q63ZY3 | protein_coding | tolerated(0.09) | probably_damaging(0.981) | TCGA-E2-A14Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| KANK2 | SNV | Missense_Mutation | novel | c.1604C>T | p.Thr535Ile | p.T535I | Q63ZY3 | protein_coding | tolerated(0.05) | possibly_damaging(0.687) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| KANK2 | SNV | Missense_Mutation | novel | c.1747N>A | p.Glu583Lys | p.E583K | Q63ZY3 | protein_coding | tolerated(0.09) | benign(0) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| KANK2 | SNV | Missense_Mutation | novel | c.236N>T | p.Ser79Phe | p.S79F | Q63ZY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KANK2 | SNV | Missense_Mutation | novel | c.287G>A | p.Arg96His | p.R96H | Q63ZY3 | protein_coding | tolerated(0.05) | possibly_damaging(0.632) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| KANK2 | SNV | Missense_Mutation | c.1122G>C | p.Glu374Asp | p.E374D | Q63ZY3 | protein_coding | deleterious(0.04) | benign(0.009) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| KANK2 | SNV | Missense_Mutation | novel | c.1831N>C | p.Lys611Gln | p.K611Q | Q63ZY3 | protein_coding | tolerated(0.07) | probably_damaging(0.929) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| KANK2 | SNV | Missense_Mutation | rs765508139 | c.1964N>T | p.Thr655Met | p.T655M | Q63ZY3 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |